What's Happening?
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have released new data from an open-label extension study of repinatrabit, an investigational drug for phenylketonuria (PKU). The study, presented at the 2026
American College of Medical Genetics and Genomics meeting, showed significant reductions in blood phenylalanine (Phe) levels in adolescents. Participants receiving a low dose of repinatrabit achieved a 67% mean reduction in Phe levels from baseline. The study is part of a broader effort to develop repinatrabit as a treatment for PKU, a genetic disorder that affects the metabolism of phenylalanine, leading to its toxic accumulation in the body. The drug is being tested in a global Phase 3 trial for adults, aiming to evaluate its efficacy and safety across different age groups.
Why It's Important?
The development of repinatrabit is significant as it offers a potential new treatment option for individuals with PKU, a condition that can lead to severe neurological and psychiatric issues if untreated. Current treatments are limited, and maintaining control of blood Phe levels is particularly challenging during adolescence, a critical period for neurodevelopment. The promising results from the study suggest that repinatrabit could provide a novel approach to managing PKU, potentially improving the quality of life for patients and reducing the risk of cognitive and psychiatric complications. This advancement could also broaden treatment options and offer a more effective management strategy for PKU, which affects approximately 1 in 10,000 individuals in the United States.
What's Next?
Otsuka is advancing the pivotal Phase 3 PheORD trial in adults with PKU, which is designed to assess the efficacy and safety of repinatrabit. The trial will enroll a broad adult PKU population and is expected to complete its primary endpoint by late 2026, with full study completion anticipated in 2028. The ongoing research and development efforts aim to establish repinatrabit as a first-in-class oral therapy for PKU, potentially transforming the treatment landscape for this genetic disorder. The results of these trials will be crucial in determining the future availability and use of repinatrabit in clinical practice.
